The RAD17-RFC2-5 Complex: A Potential Drug Target for Neurological Disorders

Target Name: RAD17-RFC2-5 complex

NCBI ID: P24975

RAD17-RFC2-5 complex

Other Name(s): None

The RAD17-RFC2-5 Complex: A Potential Drug Target for Neurological Disorders

The RAD17-RFC2-5 complex is a protein that is expressed in various tissues of the body, including the brain, and is involved in the regulation of cellular processes that are crucial for brain development and function. The complex consists of three subunits: RAD17, RFC2, and RFC5.

RAD17 is a histone-remodeling enzyme that is involved in the histone-coding process, which is the process by which proteins are translated from DNA into their functional forms. RAD17 functions as a negative regulator of the histone-coding process, which means that it prevents the addition of non-histone DNA sequences to the histone tails.

RFC2 is a protein that is involved in the regulation of gene expression. It functions as a positive regulator of the expression of target genes by binding to specific DNA sequences and promoting the access of these genes to the RNA polymerase.

RFC5 is a protein that is involved in the regulation of cellular processes that are crucial for brain development and function. It functions as a negative regulator of the migration of neurons, which are a type of cell that are responsible for transmitting signals throughout the brain.

The RAD17-RFC2-5 complex plays a crucial role in the regulation of cellular processes that are crucial for brain development and function. The complex functions as a negative regulator of the histone-coding process, which is the process by which proteins are translated from DNA into their functional forms. It also functions as a positive regulator of the expression of target genes by binding to specific DNA sequences and promoting the access of these genes to the RNA polymerase. Additionally, it functions as a negative regulator of the migration of neurons, which are a type of cell that are responsible for transmitting signals throughout the brain.

The RAD17-RFC2-5 complex is a potential drug target for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The complex is also a potential biomarker for the early detection of these disorders.

The RAD17-RFC2-5 complex is a protein that is expressed in various tissues of the body, including the brain, and is involved in the regulation of cellular processes that are crucial for brain development and function. The complex consists of three subunits: RAD17, RFC2, and RFC5. RAD17 is a histone-remodeling enzyme that is involved in the histone-coding process, RFC2 is a protein that is involved in the regulation of gene expression, and RFC5 is a protein that is involved in the regulation of cellular processes that are crucial for brain development and function. The RAD17-RFC2-5 complex plays a crucial role in the regulation of cellular processes that are crucial for brain development and function, and the complex is a potential drug target and biomarker for the treatment of various neurological disorders.

Protein Name: RAD17-RFC2-5 Complex

The "RAD17-RFC2-5 complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD17-RFC2-5 complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets